AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 12 min read$ALKS

Hopkinson Craig C. sold $375K of ALKS

Hopkinson Craig C. (EVP R&D, Chief Medical Officer) sold 9,000 shares of Alkermes plc. (ALKS) at $41.67 ($0.38M total) on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Hopkinson Craig C.
Published Jun 1, 2026, 11:26 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 1, 2026, 11:31 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$ALKS
Neutral
high confidence
Mentioned
$ALKS
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALKSNeutralLow
01

Why it matters

Absent any accompanying company-specific news (earnings, trial results, approvals, deals, litigation), the disclosure mainly informs positioning/sentiment rather than fundamentals.

02

Market read

Traders may monitor for follow-on insider activity, but this specific Form 4 alone is unlikely to drive a durable repricing.

03

What to watch

10b5-1 plans are pre-scheduled and often driven by liquidity/tax planning, reducing the signal-to-noise of insider selling.

Relevance 6/10Novelty 2/10Timing: Filed same day (2026-06-01) as the sale; potential intraday sentiment check.

Background

The filing is an SEC Form 4 for an Alkermes executive (EVP R&D, Chief Medical Officer) reporting an open-market sale executed under a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$ALKSNeutralHigh confidence
Context

Alkermes (ALKS) disclosed an officer open-market sale: 9,000 shares sold on 2026-06-01 under a pre-arranged 10b5-1 plan.

Expected impact

Low likelihood of sustained price impact; any reaction is likely limited and quickly mean-reverting.

Evidence & confidence

Form 4 insider sales under a pre-arranged 10b5-1 plan typically have limited informational content versus buys tied to new events.

Market effects

Sector

Minimal; single-company insider transaction without accompanying guidance/clinical/regulatory updates.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

If the sale volume is unusually large relative to prior patterns, traders could briefly interpret it as caution—even with a 10b5-1 plan.

Key entities

  • issuer
    Alkermes plc

    Subject of the insider transaction disclosure (Form 4) reporting an officer sale of ALKS shares.

  • insider
    Hopkinson Craig C.

    EVP R&D and Chief Medical Officer who sold 9,000 shares on 2026-06-01 under a 10b5-1 plan.

Read at source← All news

Related articles

JUL 30
$ALKSMed

Alkermes plc Q2 2026 Earnings Call Summary

Strategic Evolution and Operational Context Management characterized the current period as a major phase of growth, with the orexin platform evolving from a hypersomnolence focus to a broad neurocircuitry platform for ADHD and fatigue. Alixorexton is positioned as a leading asset, being the only orexin 2 receptor agonist to demonstrate efficacy and tolerability across both NT1 and NT2 in large Phase 2 studies.

yahoo.com6 min
JUL 28
$ALKSMedAI 8/10

Alkermes plc. (ALKS): Results of Operations and Financial Condition

Alkermes plc. (ALKS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 alks-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Alkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Katie Joyce +1 781 249 8927 Alkermes plc Reports Second Quarter 2026 Financial Results — Second Quarter Revenues of $496.0 Million — — GAAP Net Income

SEC EDGAR 8-K6 min
JUL 25
$ALKSMed

Interim Analysis: Sustained Wakefulness with Alixorexton in Narcolepsy

Alkermes plc reported interim results from a long-term extension study of alixorexton in adults with narcolepsy type 1 and type 2. At week 24, alixorexton showed sustained improvements on the Maintenance of Wakefulness Test and Epworth Sleepiness Scale, with mean MWT sleep latency about 29 minutes (NT1) and 18 minutes (NT2) and mean ESS about 7.5 (NT1) and 8.9 (NT2). No serious treatment-emergent adverse events were reported.

sleepreviewmag.com5 min
JUL 23
$ALKSMed

First MS Mobility Drug Gets Green Light From NHS England

NHS England said it will make fampridine (Fampyra), a pill for adults with multiple sclerosis-related walking impairment, routinely available on the NHS after a Clinical Priorities Advisory Group review. NHSE cited trials showing improved walking speed in 43% of patients and about a 25% speed increase, with ~5,000 eligible patients in England in year one. The decision follows a 2022 NICE cost-effectiveness refusal and the expiry of the Fampyra brand patent.

medscape.com4 min